U.S. Luxury Stock News

Over the past year, many Sanmina Corporation ( NASDAQ:SANM ) insiders sold a significant stake in the company which may...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...

We feel now is a pretty good time to analyse LifeStance Health Group, Inc.'s ( NASDAQ:LFST ) business as it appears the...

On October 22, 2025, DataVault AI, Inc. and Wellgistics Health, Inc. announced a non-binding letter of intent to integrate manufacturer-to-patient blockchain-enabled smart contracts into Wellgistics' prescription drug infrastructure, aiming to fully digitize tracking from script to fulfillment across more than 6,500 pharmacies nationwide. A unique aspect of this partnership is its focus on leveraging AI agents and digital routing tools to optimize prescription drug services while enhancing...

Thinking about what to do with TKO Group Holdings stock? If you own shares or are sizing up an entry, you’re probably weighing not only its impressive run but also wondering whether there is real value left or just excitement. TKO has certainly been hard to ignore. The stock has surged 63.6% over the past year, and it is up 30.9% year-to-date, showing strength most markets would envy. Even after a recent dip of 1.3% in the last week and a 6.1% slide over the last month, it is clear that the...

If you’ve found yourself eyeing Graham Holdings after its most recent moves, you’re not alone. Whether you’re considering holding, trimming, or jumping in fresh, the stock’s behavior lately has gotten plenty of investors talking. Despite facing a pullback of 13.7% over the last 30 days, which might have rattled less seasoned hands, Graham Holdings is still up an impressive 18.1% year to date and 33.8% over the past year. Step back further, and you see gains of 67.4% across three years and...

Ventyx Biosciences recently announced positive topline results from its Phase 2 clinical trial of VTX3232, showing significant reductions in key inflammatory biomarkers such as hsCRP and IL-6 in patients with obesity and cardiovascular risk factors. An interesting insight from the study is that VTX3232 achieved a robust safety and tolerability profile, both as a standalone therapy and in combination with semaglutide, highlighting its potential as a new oral anti-inflammatory option in...

If you’ve been eyeing CECO Environmental and wondering whether it’s time to get in, stay patient, or take wins off the table, you’re not alone. This stock has been quietly (and not so quietly) rewarding attentive investors with some eye-popping returns. Just check out the numbers: up 6.7% over the past week, 5.9% in the last month, and an astonishing 66.1% so far this year. Zoom out further, and the gains are even more impressive: nearly 95% for the past year and a staggering 637% over the...

Paul Mueller (MUEL) posted a noteworthy turnaround in its recent earnings, swinging to profitability over the past year after a stretch of losses. Earnings have accelerated at an average annual rate of 41.3% over the last five years, and the company’s net profit margin has expanded as profitability returned. The latest data points to attractive value with shares trading below estimated fair value, but investors should keep an eye on the high proportion of non-cash earnings when weighing the...

Bullish momentum is building around Churchill Capital Corp X (CCCX) as options traders pile into call contracts. Volumes have doubled the norm and implied volatility is spiking. The extremely low Put/Call Ratio suggests that optimism is widespread. See our latest analysis for Churchill Capital Corp X. After a quiet start to the year, Churchill Capital Corp X’s share price has climbed significantly in recent weeks, notching a 51.8% gain over the past month and doubling since the beginning of...

Core Scientific (CORZ) extended its streak of unprofitability this quarter, with net losses having grown at an average rate of 23.1% per year over the past five years. Looking ahead, analysts forecast an 83.98% annual growth in earnings and expect the company to achieve profitability within three years, while revenue is projected to expand at 36.3% per year, well above the US market average. Despite these optimistic growth projections, Core Scientific’s net profit margin has yet to show...

World Kinect (NYSE:WKC) remains unprofitable, with losses deepening at an average rate of 45.7% per year over the last five years and no improvement in its net profit margin this year. Revenue is forecast to edge down slightly by 0.01% per year in the near term, but the major storyline is an expected earnings turnaround. Analysts see profits growing by 125.91% per year, with the company potentially returning to profitability within three years, an outlook that stands out in the sector. See...

MoneyGram Haas F1 Team recently announced a new partnership with CSG Systems International, debuting their collaboration at the 2025 Formula 1 United States Grand Prix in Austin, Texas, to emphasize their shared commitment to innovation and performance. This partnership leverages the global exposure and fast-paced environment of Formula 1 racing to highlight CSG's expertise in empowering brands to engage customers and manage complexity. We'll now examine how CSG's new Formula 1 alliance...

Arcturus Therapeutics Holdings (ARCT) drew intense investor attention after it released interim results from a Phase 2 trial for its cystic fibrosis treatment, ARCT-032. The report showed no substantial lung function improvement, which triggered sharp share declines and analyst downgrades. See our latest analysis for Arcturus Therapeutics Holdings. It has been a turbulent year for Arcturus Therapeutics. Shares have dropped sharply after underwhelming trial news and legal scrutiny, leading to...

Coya Therapeutics has completed a $20 million follow-on equity offering. The company aims to strengthen its cash position and accelerate progress in the Phase 2 trial of COYA 302, its experimental ALS therapy. Investors are watching these milestones closely, as the FDA's recent acceptance of Coya's drug application and a triggered milestone payment bring new attention to the company’s clinical and financial strategy. See our latest analysis for Coya Therapeutics. After announcing the equity...

ETHZilla is drawing attention after unveiling a $15 million strategic partnership with Satschel, Inc., parent of Liquidity.io. This collaboration gives ETHZilla a 15% equity stake as well as exclusive rights within regulated digital asset markets. See our latest analysis for ETHZilla. Momentum has picked up again for ETHZilla after the Satschel investment, with the share price jumping 17.38% in just the last day and 7.32% over the past week, though recent news-fueled rallies come against the...

Thinking about whether to buy, sell, or simply hold WEC Energy Group stock? You’re definitely not alone. WEC has been a staple for many portfolios, and its share price reflects that consistency. Over the last year, the stock has climbed 23.3%. For longer-term investors, the gains are even more solid, with a 40.8% increase over the last three years and 35.9% over five years. Even its performance year to date hasn’t gone unnoticed, jumping 23.2%. That said, the past week brought a modest 0.9%...

Earlier this week, Luminar Technologies announced that its lidar technology is now integrated into Volvo’s EX90 and is being included on platforms from Mercedes-Benz, NVIDIA, and Mobileye, while it also provided updates on its next-generation “Halo” chipset and production plans for late 2025 and early 2026. An interesting takeaway is that despite these prominent partnerships and advancements, the company revised its full-year 2025 guidance downward due to slower automotive ramp-up, winding...

Eightco Holdings (ORBS) is in the spotlight again after its move to adopt Worldcoin as a primary reserve asset and bring Dan Ives on board as chairman. This shake-up has sparked renewed interest and rapid price swings. See our latest analysis for Eightco Holdings. ORBS has seen one of the most dramatic runs among speculative stocks this year, with the 1-year total shareholder return at nearly 231%. Yet, this surge comes after years of heavy losses, a delisting, and repeated pivoting between...

Flux Power Holdings (FLUX) has regained compliance with Nasdaq’s listing rules after facing a potential delisting. This development is likely to boost investor confidence and renew interest in the company’s prospects. See our latest analysis for Flux Power Holdings. Regaining Nasdaq compliance comes after a dramatic surge in Flux Power Holdings’ share price, with a 30-day share price return of 85.5% and a striking year-to-date gain of 252.9%. That momentum has reignited interest, especially...

Picard Medical (PMI) shares dropped sharply after the company’s recent SEC filing revealed an expanded equity incentive plan. The filing increased authorized shares and added new types of stock awards, sparking fresh concerns over possible shareholder dilution. See our latest analysis for Picard Medical. The latest shakeup at Picard Medical comes on the heels of its recent IPO and the unveiling of new patents for its artificial heart technology. However, none of that cushioned the blow from...

Despite the fact that PubMatic, Inc. (NASDAQ:PUBM) stock rose 10% last week, insiders who sold US$319k worth of stock...

The recent 10% drop in Marten Transport, Ltd.'s ( NASDAQ:MRTN ) stock could come as a blow to insiders who purchased...